US10106816B2ActiveUtilityA1
Genomic RNA packaging enhancer element
Est. expiryDec 14, 2032(~6.4 yrs left)· nominal 20-yr term from priority
Inventors:Eric J. Arts
C07K 14/005C12N 2740/16043C12N 15/86C12N 2740/15042C12N 2740/16222C12N 2740/15052
63
PatentIndex Score
0
Cited by
5
References
11
Claims
Abstract
A synthetic lentiviral vector construct comprises a genomic RNA packaging enhancer (GRPE) element and lentiviral nucleic acid sequences sufficient for reverse transcription and packaging in a host cell.
Claims
exact text as granted — not AI-modifiedHaving described the invention, the following is claimed:
1. A method of enhancing the infectivity of recombinant HIV-1 particles produced from a cell transfected with an HIV-1 lentiviral vector construct, the method comprising:
administering to the cell an HIV-1 lentiviral vector construct comprising a genomic RNA packaging enhancer (GRPE) element, HIV-1 lentiviral nucleic acid sequences sufficient for reverse transcription and packaging in the cell, and a regulatory sequence sufficient for transcription operably linked to a nucleic acid segment that encodes an RNAi agent or a shRNA, wherein the GRPE element comprises a nucleic acid sequence corresponding to a nucleic acid sequence encoding the P2 and P3 stem loops in the gag p1-p6 domain of the HIV-1 RNA wild-type genome, the GRPE element comprising a nucleic acid sequence having SEQ ID NO:1, wherein the presence of the GRPE in the HIV-1 lentiviral vector construct increases HIV-1 genomic RNA packaging in the recombinant HIV-1 particles produced by the transfected cell, and wherein the increase in HIV-1 genomic RNA packaging is positively correlated to the infectivity of the recombinant HIV-1 particles released from the transfected cell.
2. The method of claim 1 , wherein the HIV-1 lentiviral vector construct is an HIV-1 lentiviral transfer plasmid or an infectious HIV-1 lentiviral particle.
3. The method of claim 1 , the regulatory sequence comprising a promoter or enhancer.
4. The method of claim 1 , the HIV-1 lentiviral vector construct further comprising a regulatory sequence operably linked to a nucleic acid segment that encodes a reporter gene.
5. The method of claim 4 , the reporter gene comprising a detectable or selectable marker gene.
6. A method of increasing the transduction efficiency of an HIV-1 lentiviral vector construct comprising:
inserting a genomic RNA packaging enhancer (GRPE) element into an HIV-1 lentiviral vector construct, wherein the GRPE element comprises a nucleic acid sequence corresponding to a nucleic acid sequence encoding the P2 and P3 stem loops in the gag p1-p6 domain of the HIV-1 RNA wild-type genome, the GRPE element comprising a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:1, wherein the GRPE element includes two or fewer nucleotide substitutions in the nucleic acid sequence corresponding to the nucleic acid sequence encoding the P2 and P3 stem loops in the pap p1-p6 domain of the HIV-1 RNA wild-type genome, the HIV-1 lentiviral vector construct comprising lentiviral nucleic acid sequences sufficient for reverse transcription and packaging and a regulatory sequence sufficient for transcription operably linked to a nucleic acid segment that encodes an RNAi agent or a shRNA;
administering the HIV-1 lentiviral vector construct including the inserted GRPE element to a first cell, wherein the presence of the GRPE element increases HIV-1 genomic RNA packaging in recombinant HIV-1 particles released from the first cell, wherein the increased HIV-1 genomic RNA packaging is positively correlated to an increase in the transduction efficiency of the recombinant HIV-1 particles when the recombinant HIV-1 particles are administered to a second cell.
7. The method of claim 6 , wherein the transduction efficiency of a recombinant HIV-1 particle is greater than the transduction efficiency of an identical recombinant HIV-1 particle not comprising a GRPE element.
8. The method of claim 6 , wherein the HIV-1 lentiviral vector construct is an HIV-1 lentiviral transfer plasmid.
9. The method of claim 6 , the regulatory sequence comprising a promoter or enhancer.
10. The method of claim 6 , the HIV-1 lentiviral vector construct further comprising a regulatory sequence operably linked to a nucleic acid segment that encodes a reporter gene.
11. The method of claim 10 , the reporter gene comprising a detectable or selectable marker gene.Join the waitlist — get patent alerts
Track US10106816B2 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.